ArticleJournal of the American Geriatrics Society2025
Preliminary Data From a Geriatrician-Led Program for Orthopedic Co-Managed Hip Fracture Patients Using Zoledronic Acid.
Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHip fractures are increasing as the U.S. population ages and result in significant morbidity, mortality, and cost. Despite guidelines recommending osteoporosis treatment after hip fracture, few patients receive treatment. To address this unmet need, our large, tertiary care, academic hospital initiated an inpatient osteoporosis treatment program with Zoledronic Acid (ZA) led by a single geriatrician co-managing patients with hip fracture admitted to the orthopedic trauma service. This study describes the program's implementation and preliminary data.
methodsA prospective cohort of older adults (>/= 65 years) with surgically repaired hip fractures at a single academic center were included from September 12th, 2022, through May 17th, 2024. The ZA program was initiated by geriatrics in collaboration with other specialties, including nursing and pharmacy. Co-managed hip fracture patients were screened for ZA. Eligibility criteria included creatinine clearance >/= 35 mL/min and Vitamin D level >/= 20 ng/mL. The RE-AIM framework was utilized to evaluate the program's implementation: Reach (number of patients admitted, screened and eligible), effectiveness (eligible patients who received ZA, reasons for ineligibility), adoption (time spent) and implementation (program cost).
resultsDuring a twenty-month period, 232 hip fracture patients with a mean age of 83.8 years were admitted to co-managed care, of which 74% were female. 148 patients were screened for ZA; 67 (45.3%) were eligible, and 58 (39.2%) received ZA prior to hospital discharge. The most common reasons for ineligibility were low vitamin D (32.1%), inadequate kidney function (21%) and previous or current osteoporosis treatment in the outpatient setting (29.6%). No adverse reactions or delays in discharge were noted among treated patients. On average, 30 min were spent on screening and treatment.
conclusionA co-managed inpatient ZA program led by a single geriatrician appears to be a feasible strategy to treat osteoporosis among hospitalized patients with hip fracture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.